Nanobiotix H1 FY26 net loss widens to €34.3 million as revenue and other operating income drops to €5.6 million
NBTX•Nanobiotix reported first-half 2026 revenue and other operating income of €5.6 million, down 78.95%, and a net loss attributable to ordinary shareholders of €34.3 million, or €0.70 per share.
1. First-half results
Revenue and other operating income fell 78.95% to €5.6 million. Net loss attributable to ordinary shareholders widened to €34.3 million, or €0.70 per share. Research and development expenses slipped to €12.7 million, while selling, general and administrative costs edged down to €10.8 million.
2. Cash and clinical updates
Cash and cash equivalents totaled €110.9 million at June 30, extending the company’s financial runway through 2029. Laurent Levy cited encouraging JNJ-1900 (NBTXR3) data across indications and a Phase 3 NANORAY-312 protocol amendment intended to enable an earlier final readout.
